PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Steroid Biochem Mol Biol. Author manuscript; available in PMC Jul 1, 2011.
Published in final edited form as:
PMCID: PMC2891066
NIHMSID: NIHMS185482
1α-hydroxylase and innate immune responses to 25-hydroxyvitamin D in colonic cell lines
Venu Lagishetty, Rene F. Chun, Nancy Q. Liu, Thomas S. Lisse, John S. Adams, and Martin Hewison
Department of Orthopaedic Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, 90095, USA
Corresponding Author: Martin Hewison, PhD, Room 410D, Orthopaedic Hospital Research Center, University of California Los Angeles, Los Angeles, CA 90095, USA, Tel: (310) 206-1625, Fax: (310) 825-5409, mhewison/at/mednet.ucla.edu
Vitamin D-insufficiency is a prevalent condition in populations throughout the world, with low serum levels of 25-hydroxyvitamin D (25OHD) linked to a variety of human health concerns including cancer, autoimmune disease and infection. Current data suggest that 25OHD action involves localized extra-renal conversion to 1,25-dihydroxyvitamin D (1,25(OH)2D) via tissue-specific expression of the enzyme 25-hydroxyvitamin D-1α-hydroxylase (1α-hydroxylase). In cells such as macrophages, expression of 1α-hydroxylase is intimately associated with toll-like receptor (TLR) recognition of pathogens. However, this mechanism may not be exclusive to extra-renal generation of 1,25(OH)2D. To investigate the relationship between TLR-mediated pathogen recognition and vitamin D-induced antibacterial activity, intracrine responses to 25OHD metabolism were explored in vitro using the established colonic cell lines Caco-2 and Caco-2 clone BBe. Analysis of antibacterial factors such as cathelicidin (LL37) and β-defensin-4 (DEFB4) was carried out following co-treatment with TLR ligands. Data indicate that, unlike macrophages, Caco-2 and BBe colonic cell lines are unresponsive to TLR-induced 1α-hydroxylase. Alternative activators of 1α-hydroxylase such as transforming growth factor β were also ineffective at priming intracrine responses to 25OHD. Thus, in common with other barrier sites such as the skin or placenta, colonic epithelial cells may require specific factors to initiate intracrine responses to vitamin D.
Keywords: vitamin D, 1α-hydroxylase, epithelial cell, macrophage, cathelicidin, defensin
Interaction between vitamin D and the immune system has been recognized for over a quarter of a century. Despite this, the potential importance of vitamin D to normal human innate immunity has only gained recognition in the last few years. Two key developments have underpinned this change in perspective. The first is that our perception of what constitutes adequate vitamin D status has changed. The observation that serum levels of the inactive form of vitamin D, 25-hydroxyvitamin D (25OHD) as high as 75 nM correlate inversely with parathyroid hormone [1] has prompted introduction of the term “vitamin D insufficiency”. This is defined by serum levels of 25OHD that are sub-optimal (< 75 nM) but not necessarily rachitic (< 20 nM) [2]. Unlike serum concentrations of active 1,25-dihydroxyvitamin D (1,25(OH)2D), which are primarily defined by renal regulators of the enzyme, 25-hydroxyvitamin D-1α-hydroxylase (1α-hydroxylase), circulating levels of 25OHD are a direct reflection of individual exposure to sunlight or dietary intake of vitamin D. As a consequence of these new parameters it is clear that the numbers of people throughout the world classified as vitamin D insufficient is much greater than originally thought [3].
The second important development to alter our perception of vitamin D concerns recent studies highlighting its potent effects on innate immunity [47]. Previous experiments by Rook and colleagues first demonstrated the ability of 1,25(OH)2D to suppress proliferation of pathogens such as Mycobacterium tuberculosis (M. tb) in macrophages [8]. However, it was not until much later that similar actions were described for 25OHD. In studies to define monocyte responses to M. tb, Modlin and colleagues demonstrated induction of the vitamin D receptor (VDR) and 1α-OHase in monocytes treated with ligand to TLR2/1, the principal pathogen recognition receptor for M. tb [9]. They were then able to demonstrate activation of monocyte target genes as a consequence of local synthesis of 1,25(OH)2D from 25OHD. The key immune target of this intracrine metabolism was cathelicidin (LL37), an antimicrobial protein known to express a functional vitamin D response element in its gene promoter [10, 11]. Induction of LL37 appears to be a crucial step in facilitating successful phago-lyzosomal killing of bacteria, particularly M. tb [12]. Significantly, ex vivo induction of LL37 in monocytes following TLR activation has been shown to correlate closely with serum levels of 25OHD, underlining the importance of intracrine vitamin D metabolism to this facet of innate immunity [9, 13].
Induction of LL37 by 1,25(OH)2D does not appear to be restricted to monocytes and macrophages. Similar activation of the antimicrobial factor has been reported in bronchial epithelial cells [14], myeloid cell lines [10], as well as decidual [15], and trophoblastic [16] cells of the placenta. However, this effect does not appear to be universal despite the ubiquitous expression of VDR [17]. The question therefore arises as to whether different parameters are required to promote vitamin D-induced innate immunity within different tissues. In the following manuscript we review reported mechanisms for regulation of 1α-OHase and LL37 in ‘barrier’ tissues such as the skin, placenta and gastrointestinal (GI) tract. In addition we present data from studies using colonic cell lines, which provide a further perspective on the role of localized synthesis of 1,25(OH)2D in promoting antimicrobial activity in cells not conventionally involved in immune responses.
2.1 Reagents
Unlabeled 1,25-dihydroxyvitamin D3 (1,25(OH)2D) and 25-hydroxyvitamin D3 (25OHD) were purchased from Biomol (Plymouth Meeting, PA). Toll-like receptor (TLR) 2 ligand 19 kDa lipopeptide (19 kDa, Invivogen, San Diego, CA, USA). TLR4 ligand lipopolysaccharide (LPS, Invivogen). [3H]25-hydroxyvitamin D3 ([3H]25OHD3, specific activity, 187 Ci/mmol) was purchased from Amersham Biosciences, Piscataway, NJ).
2.2 Cell Culture
The Caco-2 colonic cell line and the BBe clone of Caco-2, (both kind gifts of Dr JC Fleet, Purdue University) were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% FCS as described previously [18]. Cell treatments were for 24 hrs and included 1,25(OH)2D (10 nM), 25OHD (100 nM), 19 kDa (1 ng/ml) and LPS (100 ng/ml). Ficoll-isolated peripheral blood mononuclear cells (PBMCs) derived from anonymous donors were obtained from the Center for AIDS Research Virology Core/BSL3 Facility (supported by the National Institutes of Health award AI-28697 and by the UCLA AIDS Institute and the UCLA Council of Bioscience Resources). Monocytic cells were isolated from PBMCs by adherence and then maintained for seven days in 24 well plates using RPMI 1640 medium supplemented with 10% FCS and granulocyte-macrophage colony-stimulating factor (GM-CSF) (Immunex, Seattle, WA). The resulting cells showed increased expression of macrophage makers such as CD14 [19].
2.3 Quantification of 1α- and 24-hydroxylase activity
Synthesis of 1,25(OH)2D by Caco-2 and BBe cells was assessed by quantifying the conversion of radiolabelled 25OHD to 1,25(OH)2D in serum-free cultures of these cells. For each assay 50 nM [3H]25OHD3 (Amersham Biosciences, Piscataway, NJ) was added to cells in 200 μl of serum-free medium and then incubated for 5 hrs at 37°C, with the reaction being terminated by freezing at −20°C. Protein from these samples was initially precipitated with added acetonitrile (1:1). Vitamin D metabolites were then extracted from the reaction mixtures by elution on C18-OH columns according to manufacturer’s instructions (Diasorin, Stillwater, MN). The resulting eluent was resuspended in 25 μl of elution solvent hexane:methanol:isopropanol (90:5:5), vortexed for 15 seconds, and individual metabolites separated by HPLC using a Beckman System Gold system with an Agilent Technologies Zobax Sil normal-phase column (Agilent Technologies, Paolo Alta, CA) eluted at a rate of 1.5ml/min for 20 minutes. Elution profiles for standard vitamin D metabolites (25OHD3, 24,25(OH)2D3, 1,25(OH)2D3) were determined by UV absorbance at 264 nm. Elution of metabolites of 3[H]-25OHD3 was assessed using a β-Ram Model 4 in-flow detector (IN/US, Tampa, Fl) in conjunction with Ultima-Flo M scintillation fluid (Perkin-Elmer, Boston, MA) at a 2:1 ratio with a 5 second dwell time to designate the increments for data collection. Lauralite 3 software (LabLogic, Sheffield, UK) was used to quantitate peaks of radioactivity corresponding to 25OHD3, 24,25(OH)2D3 or 1,25(OH)2D3. Data were reported as mean fmoles metabolite synthesized/hr/mg cellular protein ± S.D. following n=3 separate incubations.
2.4 Quantitative PCR analysis of gene expression
RNA was extracted from mouse tissues using the RNeasy Total RNA extraction kit as detailed by the manufacturer (Qiagen, Valencia, CA). RNA was eluted in RNase-free elution solution and aliquots (1.5 μg) were reverse-transcribed using Powerscript MMLV reverse transcriptase as described by the manufacturer (ABI, Foster City, CA). Expression of target gene mRNA was quantified using an ABI 7700 sequence detection system (ABI, Foster City, CA) as described previously [20]. Approximately 50 ng of cDNA were used per reaction. All reactions were multiplexed with the housekeeping gene 18S rRNA, provided as an optimised control probe labeled with VIC fluorochrome (ABI), enabling data to be expressed in relation to an internal reference to allow for differences in sampling. The fluorogenic probes for target genes were labeled with five-carboxy fluorescein (FAM). Data were obtained as Ct values (the cycle number at which logarithmic PCR plots cross a calculated threshold line), and used to determine ΔCt values (Ct of target gene–Ct of housekeeping gene, 18S rRNA). All reactions were performed in triplicate and expressed as a mean of these values. PCR amplification of target gene cDNA was carried out using the following Taqman human gene expression assays: 1α-OHase, Assays-on-Demand (ABI) primer and probe mix Hs01096149; LL37, Hs00189038_m1; DEFB4 Hs00175474_m1; 24-OHase, Hs Hs00167999_m1 (CYP24A1). cDNAs were amplified under the following conditions: 50 °C for 2 min; 95 °C for 10 min; followed by 44 cycles of 95 °C for 15 sec and 60 °C for 1 min.
2.5 Statistics
Where indicated, experimental means were compared statistically using one way analysis of variance (ANOVA) with the Holm-Sidak method used as a post hoc multiple comparison procedure and Sigmaplot Software (Systat Inc., San Jose, CA, USA). Statistical analyses were carried out using raw ΔCt values.
Studies were initially carried out to assess metabolism of 25OHD in two colonic cell lines, Caco-2 and a sub-clone of Caco-2 (BBe) able to develop an enterocyte-like phenotype with features of mature, small-intestinal epithelial cells [18]. Both Caco-2 and BBe colonic cell lines demonstrated the capacity to synthesize 1,25(OH)2D and 24,25(OH)2D from 25OHD (Figure 1A). For Caco-2 cells, neither enzyme activity was influenced by exposure to ligand for TLR2 (19 kDa) or TLR4 (LPS). BBe cells showed a small but significant increase in 1,25(OH)2D production when treated with LPS, although 24-OHase activity was unaffected by the TLR4 ligand. The capacity for synthesis of 1,25(OH)2D in untreated Caco-2 (27 ± 4 fmoles/hr/mg protein) and BBe cells (32 ± 1 fmoles/hr/mg protein) was lower than that observed for human macrophages (135 ± 16 fmoles/hr/mg protein for peripheral blood monocytes cultured for 7 days). Likewise, 24-OHase activity in untreated Caco-2 (31 ± 3 fmoles/hr/mg protein) and BBe cells (19 ± 2 fmoles/hr/mg protein) was lower than that observed for human monocytes (117 ± 19 fmoles/hr/mg protein). For both BBe and Caco-2 cells none of the treatments had any significant effect on expression of mRNA for 1α-hydroxylase (Figure 1B).
Figure 1
Figure 1
Toll-like receptor regulation of vitamin D metabolism and 1α-hydroxylase expression in colonic cell lines
Previous studies have shown that both Caco-2 and BBe cells are sensitive to 1,25(OH)2D. Further studies were therefore carried out to determine whether endogenous 1α-OHase activity in Caco-2 or BBe cells was able to support induction of the antimicrobial proteins LL37 and DEFB4, which are both characterized by the presence of vitamin D response elements in their gene promoters [10, 11]. Data in Figure 2A indicated that there was low baseline expression of LL37 in untreated BBe cells and this was unaffected by treatment with 19 kDa, LPS or 25OHD alone. However, co-treatment of BBe cells with 25OHD and 19 kDa or LPS significantly elevated LL37 expression. Treatment with 1,25(OH)2D induced LL37 to levels equivalent to LPS/19 kDa in combination with 25OHD (data not shown). By contrast, 1,25(OH)2D stimulated a 250-fold induction of 24-OHase mRNA in BBe cells, whilst 25OHD in combination with LPS produced only a 10-fold induction of 24-OHase (data not shown).
Figure 2
Figure 2
Toll-like receptor regulation of intracrine induction of antimicrobial agents in colonic cell lines
In untreated Caco-2 cells expression of LL37 was 6-fold higher than corresponding BBe cells. However, in contrast to the BBe cells, treatment with the TLR2 or TLR ligands acted to suppress expression of LL37. Treatment with 25OHD alone had no effect on Caco-2 LL37 but the suppressive effects of 19 kDa and LPS were not observed when used in combination with 25OHD. As with BBe cells, treatment of Caco-2 with 1,25(OH)2D (10 nM, 24hrs) induced LL37 to levels equivalent to combined LPS/19 kDa and 25OHD (data not shown). However, these responses to 1,25(OH)2D were paralleled by a 500-fold induction of 24-OHase mRNA in Caco-2 cells, whereas treatment with 25OHD in combination with LPS produced only a 7-fold induction of 24-OHase (data not shown).
Low baseline expression of DEFB4 was also observed in the colonic cell lines, with no apparent difference between Caco-2 and BBe cells (Figure 2B). In both cell lines LPS potently induced DEFB4, whilst 19 kDa and 25OHD had no effect. Interestingly, combined treatment with 25OHD attenuated the stimulatory effects of LPS on DEFB4 in both cell lines.
TLR induction of intracrine metabolism of vitamin D appears to be central to bacterial killing by monocytes. However, given the widespread expression of both 1α-OHase and VDR in cells at extra-renal sites [21, 22], it is likely that similar induction of innate immunity will occur in these tissues. Nevertheless, studies to date indicate that although VDR-mediated induction of LL37 is characteristic of several cell types [10, 1416], it is not universal. Thus, although many cells may exhibit the potential for localized synthesis of 1,25(OH)2D from 25OHD, the in vivo impact of this on key physiological mechanisms such as LL37 expression may be dependent on tissue-specific factors. Data presented here indicate that although both Caco-2 and BBe cell lines express 1α-OHase and produce endogenous 1,25(OH)2D, only BBe cells showed a modest intracrine induction of LL37 using 100 nM 25OHD as substrate. No intracrine induction of LL37 was observed in Caco-2 cells, consistent with previous studies [17]. The differential responsiveness of colonic cells with respect to LL37 does not appear to be due to altered sensitivity to 1,25(OH)2D, as BBe cells appear to express lower levels of VDR than Caco-2 cells [18]. Thus, it seems likely that antimicrobial responses at sites such as the GI tract will involve complex microenvironmental factors that either influence vitamin D responsiveness or act independently on agents such as LL37.
Barrier site elaboration of vitamin D-induced innate immunity has been most well studied using epidermal keratinocytes which, like monocytes, demonstrate synthesis of 1,25(OH)2D and intracrine induction of LL37 [23]. As with monocytes, these effects can be stimulated following TLR2-activation. However, because keratinocytes express low levels of TLR, initial induction of these receptors is required to facilitate pathogen-sensing [23], a function that can be fulfilled by 1,25(OH)2D. Basal expression of 1α-OHase by keratinocytes is stimulated by transforming growth factor beta 1 (TGF-β1), and this alternative activation pathway appears to be sufficient for 1,25(OH)2D upregulation of TLR2 leading, in turn, to amplification of LL37 production similar to that described for macrophages [23]. In human skin, expression of TGF-β1 is a feature of tissue injury and thus vitamin D-mediated LL37 expression may be part of a mechanism linking wound repair with enhanced innate immune surveillance [23]. The precise integration of mechanisms associated with vitamin D and innate immunity in the skin versus immune cells such as monocytes remains to be elucidated. In particular, it is interesting to contrast the positive action of 1,25(OH)2D on keratinocyte TLR expression [23], with the 1,25(OH)2D-mediated suppression of TLR2 and TLR4 reported for monocytes [24].
In contrast to monocytes, colonic epithelial cells and keratinocytes, 1,25(OH)2D appears to be constitutively synthesized by cells from the placenta [25, 26]. Expression of 1α-OHase and VDR is profoundly elevated in maternal decidua and fetal trophoblast early in the first trimester of pregnancy, remaining elevated until the third trimester [20]. Initially, this was linked to the rise in maternal serum 1,25(OH)2D that occurs at the end of the first trimester. However, studies of 1α-OHase-deficient animals and anephric pregnant women indicate that this is not likely to be the case [27]. Instead, the presence of VDR in the placenta suggests that vitamin D functions in an autocrine fashion at the fetal-maternal interface [28]. One possible explanation is that 1,25(OH)2D functions as a regulator of placental calcium transport [28], but an immunomodulatory function has also been proposed [29]. The latter stems, in part, from studies highlighting immunological, barrier function of the heterogeneous cells that make up the placenta. Maternal and fetal cells are able to mediate innate and adaptive immune responses. In primary cultures of human decidual cells we showed that both 1,25(OH)2D and 25OHD (the latter metabolized endogenously to 1,25(OH)2D) induced expression of LL37, whilst suppressing inflammatory cytokine production [15]. More recently we have demonstrated that cultured trophoblastic cells also show potent induction of LL37, suggesting that similar innate immune responses to locally metabolized 25OHD occur in both maternal and fetal tissues [16]. In view of the fact that infection during pregnancy is a prevalent cause of preterm birth and fetal mortality, it is tempting to speculate that the constitutive elevation of 1α-OHase in the placenta provides an optimal system for maintaining innate immune surveillance during pregnancy. As yet, the mechanism for induction of 1α-OHase in decidua and trophoblasts remains unclear. However, in common with monocytes, keratinocytes and colonic cells, the efficacy of this intracrine system will be highly dependent on available 25OHD, in other words vitamin D status.
In summary, studies over the last five years have shown that local conversion of 25OHD to 1,25(OH)2D potently induces innate antimicrobial effects in a variety of tissue types. As outlined in Figure 3, the precise mechanism involved in upregulating 1α-OHase activity is likely to vary depending on the cell type involved. The roles of TLR signaling and injury-induced TGFβ expression have been well documented for peripheral blood monocytes and epidermal keratinocytes respectively (Figure 3A and B). By contrast, the factors associated with regulation of 1α-OHase expression and activity in barrier tissues such as the placenta and GI tract (Figure 3C and D) are less clear. To address this issue, future studies will need to consider the site-specific microenvironmental factors that impact on these tissues. In the colonic epithelial cells, it is important to recognize that the GI tract is routinely exposed to billions of enteric bacteria acting as commensals within the endogenous microbiota. Thus, regulation of the vitamin D system and antimicrobial activity may be very different from that observed in the skin or placenta where exposure to bacteria is normally minimized. Prospective studies will need to consider the possibility that immunoregulation of the vitamin D system within the GI tract involves pathogen-recognition receptors other than TLR2 and 4. In particular, TLR5, which plays a pivotal role in directing colonic mucosal discrimination between pathogenic and commensal bacteria [30] and TLR3, which protects against experimental colitis when activated in the GI tract [31], have yet to be extensively studied with respect to the vitamin D axis. Further characterization of these pathogen recognition receptors, together with the use of in vivo models for controlled bacterial colonization will help to shed new light on the factors that control the vitamin D metabolism/signaling axis within the GI tract.
Figure 3
Figure 3
Mechanisms for involvement of 1α-hydroxylase in antimicrobial responses within different barrier tissues
Acknowledgments
Grant support: NIH grant AR050626 to MH
Footnotes
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
1. Chapuy MC, Preziosi P, Maamer M, Arnaud S, Galan P, Hercberg S, Meunier PJ. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int. 1997;7(5):439–443. [PubMed]
2. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int. 2005;16(7):713–716. [PubMed]
3. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–281. [PubMed]
4. Hewison M. Vitamin D and innate immunity. Curr Opin Investig Drugs. 2008;9(5):485–490. [PubMed]
5. Adams JS, Hewison M. Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab. 2008;4(2):80–90. [PMC free article] [PubMed]
6. White JH. Vitamin D signaling, infectious diseases and regulation of innate immunity. Infect Immun. 2008 [PMC free article] [PubMed]
7. Bikle DD. Vitamin D and the immune system: role in protection against bacterial infection. Curr Opin Nephrol Hypertens. 2008;17(4):348–352. [PubMed]
8. Rook GA, Steele J, Fraher L, Barker S, Karmali R, O’Riordan J, Stanford J. Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology. 1986;57(1):159–163. [PubMed]
9. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zugel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311(5768):1770–1773. [PubMed]
10. Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. Faseb J. 2005;19(9):1067–1077. [PubMed]
11. Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, Tavera-Mendoza L, Lin R, Hanrahan JW, Mader S, White JH. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol. 2004;173(5):2909–2912. [PubMed]
12. Liu PT, Stenger S, Tang DH, Modlin RL. Cutting Edge: Vitamin D-Mediated Human Antimicrobial Activity against Mycobacterium tuberculosis Is Dependent on the Induction of Cathelicidin. J Immunol. 2007;179(4):2060–2063. [PubMed]
13. Adams JS, Ren S, Liu PT, Chun RF, Lagishetty V, Gombart AF, Borregaard N, Modlin RL, Hewison M. Vitamin d-directed rheostatic regulation of monocyte antibacterial responses. J Immunol. 2009;182(7):4289–4295. [PMC free article] [PubMed]
14. Yim S, Dhawan P, Ragunath C, Christakos S, Diamond G. Induction of cathelicidin in normal and CF bronchial epithelial cells by 1,25-dihydroxyvitamin D(3) J Cyst Fibros. 2007 [PMC free article] [PubMed]
15. Evans KN, Nguyen L, Chan J, Innes BA, Bulmer JN, Kilby MD, Hewison M. Effects of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 on cytokine production by human decidual cells. Biol Reprod. 2006;75(6):816–822. [PubMed]
16. Liu N, Kaplan AT, Low J, Nguyen L, Liu GY, Equils O, Hewison M. Vitamin D Induces Innate Antibacterial Responses in Human Trophoblasts via an Intracrine Pathway. Biol Reprod. 2009;80(3):398–406. [PMC free article] [PubMed]
17. Schauber J, Dorschner RA, Yamasaki K, Brouha B, Gallo RL. Control of the innate epithelial antimicrobial response is cell-type specific and dependent on relevant microenvironmental stimuli. Immunology. 2006;118(4):509–519. [PubMed]
18. Fleet JC, Eksir F, Hance KW, Wood RJ. Vitamin D-inducible calcium transport and gene expression in three Caco-2 cell lines. Am J Physiol Gastrointest Liver Physiol. 2002;283(3):G618–625. [PubMed]
19. Hewison M, Burke F, Evans KN, Lammas DA, Sansom DM, Liu P, Modlin RL, Adams JS. Extra-renal 25-hydroxyvitamin D3–1alpha-hydroxylase in human health and disease. J Steroid Biochem Mol Biol. 2007;103(3–5):316–321. [PubMed]
20. Zehnder D, Evans KN, Kilby MD, Bulmer JN, Innes BA, Stewart PM, Hewison M. The ontogeny of 25-hydroxyvitamin D(3) 1alpha-hydroxylase expression in human placenta and decidua. Am J Pathol. 2002;161(1):105–114. [PubMed]
21. Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM, Hewison M. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab. 2001;86(2):888–894. [PubMed]
22. Hewison M, Zehnder D, Chakraverty R, Adams JS. Vitamin D and barrier function: a novel role for extra-renal 1 alpha-hydroxylase. Mol Cell Endocrinol. 2004;215(1–2):31–38. [PubMed]
23. Schauber J, Dorschner RA, Coda AB, Buchau AS, Liu PT, Kiken D, Helfrich YR, Kang S, Elalieh HZ, Steinmeyer A, Zugel U, Bikle DD, Modlin RL, Gallo RL. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J Clin Invest. 2007;117(3):803–811. [PMC free article] [PubMed]
24. Sadeghi K, Wessner B, Laggner U, Ploder M, Tamandl D, Friedl J, Zugel U, Steinmeyer A, Pollak A, Roth E, Boltz-Nitulescu G, Spittler A. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol. 2006;36(2):361–370. [PubMed]
25. Gray TK, Lester GE, Lorenc RS. Evidence for extra-renal 1 alpha-hydroxylation of 25-hydroxyvitamin D3 in pregnancy. Science. 1979;204(4399):1311–1313. [PubMed]
26. Weisman Y, Harell A, Edelstein S, David M, Spirer Z, Golander A. 1 alpha, 25-Dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 in vitro synthesis by human decidua and placenta. Nature. 1979;281(5729):317–319. [PubMed]
27. Kovacs CS, Kronenberg HM. Maternal-fetal calcium and bone metabolism during pregnancy, puerperium, and lactation. Endocr Rev. 1997;18(6):832–872. [PubMed]
28. Bruns ME, Bruns DE. Vitamin D metabolism and function during pregnancy and the neonatal period. Ann Clin Lab Sci. 1983;13(6):521–530. [PubMed]
29. Rebut-Bonneton C, Demignon J. Effects of 1,25-dihydroxyvitamin D3 on in vitro lymphocyte reactions: arguments for a role at the maternofetal interface. Gynecol Obstet Invest. 1991;32(3):134–138. [PubMed]
30. Rumbo M, Nempont C, Kraehenbuhl JP, Sirard JC. Mucosal interplay among commensal and pathogenic bacteria: lessons from flagellin and Toll-like receptor 5. FEBS Lett. 2006;580(12):2976–2984. [PubMed]
31. Vijay-Kumar M, Wu H, Aitken J, Kolachala VL, Neish AS, Sitaraman SV, Gewirtz AT. Activation of toll-like receptor 3 protects against DSS-induced acute colitis. Inflamm Bowel Dis. 2007;13(7):856–864. [PubMed]